Literature DB >> 19866337

Treosulfan-based conditioning regimen in a second matched unrelated peripheral blood stem cell transplantation for a pediatric patient with CGD and invasive aspergillosis, who experienced initial graft failure after RIC.

Maja Agnieszka Klaudel-Dreszler1, Krzysztof Kalwak2, Magdalena Kurenko-Deptuch3, Beata Wolska-Kusnierz3, Edyta Heropolitanska-Pliszka3, Barbara Pietrucha3, Bożena Mikoluc4, Ewa Gorczyńska5, Marek Ussowicz5, Alicja Chybicka5, Ewa Bernatowska3.   

Abstract

Chronic granulomatous disease (CGD) is a rare primary immunodeficiency caused by a defect of phagocyte NADPH-oxidase and characterized by severe, recurrent bacterial and fungal infections. Invasive aspergillosis (IA) is the leading cause of mortality in patients with CGD. We report the case of a 3-year-old boy with CGD, who developed IA despite antifungal prophylaxis. His treatment consisted of a 10-month-long multi-drug antifungal therapy, together with surgery, but these did not cause any substantial clinical improvement. BMT in high-risk patients with CGD remains a challenge due to both, higher risk of graft rejection and inflammatory flare in the course of immune recovery. Our patient rejected the first matched unrelated donor (MUD) allograft after RIC regimen recommended by the EBMT Inborn Errors Working Party for high-risk patients. After treosulfan-based conditioning and second MUD peripheral blood stem cell transplantation both, full reconstitution of the granulocytic series and complete recovery from IA, were achieved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19866337     DOI: 10.1007/s12185-009-0433-z

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  24 in total

Review 1.  Invasive aspergillosis in primary immunodeficiencies.

Authors:  N G Almyroudis; S M Holland; B H Segal
Journal:  Med Mycol       Date:  2005-05       Impact factor: 4.076

2.  Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications.

Authors:  D W Beelen; R Trenschel; J Casper; M Freund; R A Hilger; M E Scheulen; N Basara; A A Fauser; B Hertenstein; H A Mylius; J Baumgart; U Pichlmeier; J R Hahn; E Holler
Journal:  Bone Marrow Transplant       Date:  2005-02       Impact factor: 5.483

3.  Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.

Authors:  Thomas J Walsh; Irja Lutsar; Timothy Driscoll; Bertrand Dupont; Maureen Roden; Parvis Ghahramani; Michael Hodges; Andreas H Groll; John R Perfect
Journal:  Pediatr Infect Dis J       Date:  2002-03       Impact factor: 2.129

4.  Allogeneic bone marrow transplantation for chronic granulomatous disease.

Authors:  J M Rappeport; P E Newburger; R M Goldblum; A S Goldman; D G Nathan; R Parkman
Journal:  J Pediatr       Date:  1982-12       Impact factor: 4.406

5.  Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study.

Authors:  T J Walsh; J L Goodman; P Pappas; I Bekersky; D N Buell; M Roden; J Barrett; E J Anaissie
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

6.  Bone marrow transplantation in chronic granulomatous disease.

Authors:  N Kamani; C S August; S D Douglas; E Burkey; A Etzioni; H W Lischner
Journal:  J Pediatr       Date:  1984-07       Impact factor: 4.406

7.  Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.

Authors:  Maria Ester Bernardo; Marco Zecca; Eugenia Piras; Adriana Vacca; Giovanna Giorgiani; Chiara Cugno; Giovanni Caocci; Patrizia Comoli; Angela Mastronuzzi; Pietro Merli; Giorgio La Nasa; Franco Locatelli
Journal:  Br J Haematol       Date:  2008-11       Impact factor: 6.998

Review 8.  Phagocyte immunodeficiencies and their infections.

Authors:  Sergio D Rosenzweig; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2004-04       Impact factor: 10.793

9.  Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation.

Authors:  Jochen Casper; Wolfgang Knauf; Thomas Kiefer; Daniel Wolff; Beate Steiner; Ulrich Hammer; Rudolf Wegener; Hans-Dieter Kleine; Stefan Wilhelm; Agnes Knopp; Gernot Hartung; Gottfried Dölken; Mathias Freund
Journal:  Blood       Date:  2003-08-28       Impact factor: 22.113

10.  Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilized granulocytes, and liposomal amphotericin-B.

Authors:  H Ozsahin; M von Planta; I Müller; H C Steinert; D Nadal; R Lauener; P Tuchschmid; U V Willi; M Ozsahin; N E Crompton; R A Seger
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

View more
  4 in total

Review 1.  Chronic granulomatous disease: overview and hematopoietic stem cell transplantation.

Authors:  Elizabeth M Kang; Betty E Marciano; SukSee DeRavin; Kol A Zarember; Steven M Holland; Harry L Malech
Journal:  J Allergy Clin Immunol       Date:  2011-04-17       Impact factor: 10.793

2.  Busulfan-fludarabine- or treosulfan-fludarabine-based myeloablative conditioning for children with thalassemia major.

Authors:  Roswitha Lüftinger; Natalia Zubarovskaya; Christina Peters; Arjan Lankester; Selim Corbacioglu; Jacques-Emmanuel Galimard; Annamaria Cseh; Elisabeth Salzer; Franco Locatelli; Mattia Algeri; Akif Yesilipek; Josu de la Fuente; Antonella Isgrò; Amal Alseraihy; Emanuele Angelucci; Frans J Smiers; Giorgia La La Nasa; Marco Zecca; Tunc Fisgin; Emel Unal; Katharina Kleinschmidt
Journal:  Ann Hematol       Date:  2022-01-09       Impact factor: 3.673

3.  Treosulfan-based conditioning for allogeneic HSCT in children with chronic granulomatous disease: a multicenter experience.

Authors:  Beatriz Morillo-Gutierrez; Rita Beier; Kanchan Rao; Lauri Burroughs; Ansgar Schulz; Anna-Maria Ewins; Brenda Gibson; Petr Sedlacek; Ladislav Krol; Brigitte Strahm; Irina Zaidman; Krzysztof Kalwak; Julie-An Talano; Ann Woolfrey; Chris Fraser; Isabelle Meyts; Ingo Müller; Jacek Wachowiak; Maria Ester Bernardo; Paul Veys; Karl-Walter Sykora; Andrew R Gennery; Mary Slatter
Journal:  Blood       Date:  2016-05-23       Impact factor: 22.113

4.  Chronic granulomatous disease: a review of the infectious and inflammatory complications.

Authors:  Eunkyung Song; Gayatri Bala Jaishankar; Hana Saleh; Warit Jithpratuck; Ryan Sahni; Guha Krishnaswamy
Journal:  Clin Mol Allergy       Date:  2011-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.